| Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis F Pietrantonio, F Petrelli, A Coinu, M Di Bartolomeo, K Borgonovo, ... European journal of cancer 51 (5), 587-594, 2015 | 632 | 2015 |
| Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth G Germano, S Lamba, G Rospo, L Barault, A Magrì, F Maione, M Russo, ... Nature 552 (7683), 116-120, 2017 | 630 | 2017 |
| Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer F Pietrantonio, R Miceli, A Raimondi, YW Kim, WK Kang, RE Langley, ... Journal of Clinical Oncology 37 (35), 3392-3400, 2019 | 444 | 2019 |
| Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical … C Cremolini, D Rossini, E Dell’Aquila, S Lonardi, E Conca, M Del Re, ... JAMA oncology 5 (3), 343-350, 2019 | 411 | 2019 |
| Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with … C Cremolini, C Antoniotti, D Rossini, S Lonardi, F Loupakis, F Pietrantonio, ... The Lancet Oncology 21 (4), 497-507, 2020 | 306 | 2020 |
| Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients L Derosa, B Routy, M Fidelle, V Iebba, L Alla, E Pasolli, N Segata, ... European urology 78 (2), 195-206, 2020 | 292 | 2020 |
| ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer F Pietrantonio, F Di Nicolantonio, AB Schrock, J Lee, S Tejpar, ... Journal of the National Cancer Institute 109 (12), djx089, 2017 | 253 | 2017 |
| Increased lactate secretion by cancer cells sustains non-cell-autonomous adaptive resistance to MET and EGFR targeted therapies M Apicella, E Giannoni, S Fiore, KJ Ferrari, D Fernández-Pérez, C Isella, ... Cell metabolism 28 (6), 848-865. e6, 2018 | 240 | 2018 |
| The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first … G Fucà, V Guarini, C Antoniotti, F Morano, R Moretto, S Corallo, ... British journal of cancer 123 (3), 403-409, 2020 | 236 | 2020 |
| Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer BO Van Emburgh, S Arena, G Siravegna, L Lazzari, G Crisafulli, G Corti, ... Nature communications 7 (1), 13665, 2016 | 216 | 2016 |
| BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis C Cremolini, M Di Bartolomeo, A Amatu, C Antoniotti, R Moretto, ... Annals of oncology 26 (10), 2092-2097, 2015 | 203 | 2015 |
| Targeting cancer metabolism: dietary and pharmacologic interventions C Vernieri, S Casola, M Foiani, F Pietrantonio, F de Braud, V Longo Cancer discovery 6 (12), 1315-1333, 2016 | 198 | 2016 |
| Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer F Pietrantonio, C Vernieri, G Siravegna, A Mennitto, R Berenato, ... Clinical cancer research 23 (10), 2414-2422, 2017 | 178 | 2017 |
| Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C MG Fakih, L Salvatore, T Esaki, DP Modest, DP Lopez-Bravo, J Taieb, ... New England Journal of Medicine 389 (23), 2125-2139, 2023 | 174 | 2023 |
| Microsatellite instability in Gastric Cancer: Between lights and shadows E Puliga, S Corso, F Pietrantonio, S Giordano Cancer treatment reviews 95, 102175, 2021 | 171 | 2021 |
| Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label … C Antoniotti, D Rossini, F Pietrantonio, A Catteau, L Salvatore, S Lonardi, ... The Lancet Oncology 23 (7), 876-887, 2022 | 170 | 2022 |
| Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer MP Roberti, S Yonekura, CPM Duong, M Picard, G Ferrere, M Tidjani Alou, ... Nature medicine 26 (6), 919-931, 2020 | 169 | 2020 |
| Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial A Sartore-Bianchi, F Pietrantonio, S Lonardi, B Mussolin, F Rua, ... Nature Medicine 28 (8), 1612-1618, 2022 | 163 | 2022 |
| Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic … R Moretto, C Cremolini, D Rossini, F Pietrantonio, F Battaglin, A Mennitto, ... The oncologist 21 (8), 988-994, 2016 | 144 | 2016 |
| Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials F Pietrantonio, G Randon, M Di Bartolomeo, A Luciani, J Chao, EC Smyth, ... ESMO open 6 (1), 100036, 2021 | 140 | 2021 |
